Trimethaphan

CHEMBL1201329 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

365.5 g/mol

LogP

3.6

Phase

4

Ganglionic blockade, now largely of historical interest, is the mechanism of trimethaphan: the agent competitively antagonises nicotinic acetylcholine receptors at both sympathetic and parasympathetic ganglia. Interrupting autonomic outflow at the ganglion produces rapid and controllable hypotension, and the effect ends quickly once infusion stops. Those properties suited it to deliberate hypotension during surgery and to hypertensive emergencies, aortic dissection in particular, where blood pressure had to be lowered precisely and reversibly by intravenous infusion. Blocking both autonomic divisions simultaneously also produces the parasympathetic effects characteristic of the class. The compound is recorded as C22H25N2OS with a mass near 365.5 g/mol.

Trimethaphan is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at both sympathetic and parasympathetic ganglia, producing rapid and controllable hypotension. It was used for controlled hypotension during surgery and for the management of hypertensive emergencies, particularly aortic dissection. Its short duration of action allowed for precise blood pressure control via intravenous infusion.

Molekularmasse

365,5000 g/mol

LogP

3,60

TPSA

24,60 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Anesthesiology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1

InChI

InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1

Molecular Formula

C22H25N2OS+

HBD / HBA

- / 1

Rotierbare Bindungen

4

Schwere Atome

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Trimethaphan is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at both sympathetic and parasympathetic ganglia, producing rapid and controllable hypotension. It was used for controlled hypotension during surgery and for the management of hypertensive emergencies, particularly aortic dissection. Its short duration of action allowed for precise blood pressure control via intravenous infusion.

Yes, Trimethaphan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201329. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 23576. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Trimethaphan auf PillFYI

Struktur

Schnelldaten

Formel: C22H25N2OS+

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.